Program Goals

Introduction

Using Vaccines in the Treatment of NSCLC

Vaccine Approach in NSCLC Targeting Tumor Antigens

Vaccines Evaluated in Phase 3 Lung Cancer Trials

Study Designs

Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)

Study Designs

Vaccines Evaluated in Phase 3 Lung Cancer Trials

Study Results

Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)

Study Results

Using Vaccines in the Treatment of NSCLC: Key Points

Immune Checkpoints and Their Inhibition

Immune Checkpoint Blockade Approach in NSCLC

Targeting the Immune System

CTLA-4: Upregulation and Blockade

CTLA-4 in the Immune Response

PD-1 and PD-L1 and PD-1/PD-L1 Blockade

PD-1/PD-L1 in the Immune Response

CTLA-4 and PD-1 Signaling Pathways

Antibody Blockade of Immune Checkpoints

Immune Checkpoints and Their Inhibition: Key Points

Immune-related Response Criteria

Evaluating Response to Immunotherapeutic Agents in Solid Tumors

Immune-Related Response Criteria

Defining Response WHO vs irRC

Defining Response (cont) WHO vs irRC

Patterns of Response to Cancer Immunotherapy

Immune-related Response Criteria:Key Points

Clinical Studies of Immune Checkpoint Inhibitor Therapy in

Advanced NSCLC

Ipilimumab + Chemotherapy in Advanced NSCLCDesign of Phase 2 Trial

Ipilimumab + Chemotherapy in Advanced NSCLC

Results

Ipilimumab + ChemotherapyHistology Subgroup Analysis

Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated

Patients With Advanced NSCLCEfficacy in Phase 1 Trials

Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated

Patients With Advanced NSCLCSafety in Phase 1 Trials

Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated

Patients With Advanced NSCLCSafety in Phase 1 Studies

Phase 1 Study of Nivolumab in Heavily Pretreated Pts With

Advanced NSCLCHistology Subgroup Analysis

Phase 1 Studies of Single Agent Immunotherapies in First-Line

Setting

Combinations With Immunotherapy in Advanced

NSCLC

Combinations With Immunotherapy in Advanced

NSCLC (cont)

Clinical Studies of Immune Checkpoint Inhibitor Therapy in

Advanced NSCLC: Key Points

Tumor PD-L1 Level as a Biomarker for Response

Relationship Between PD-L1 Tumor Status and Response to PD-1 and

PD-L1 Inhibitors

Relationship Between PD-L1 Tumor Status and Response to PD-1 and

PD-L1 Inhibitors (cont)

Other Immune Checkpoint Targets

Some Other Immune Checkpoint Protein Targets

Some Other Immune Checkpoint Protein Targets (cont)

Ongoing Phase 3 Clinical Trials of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

Some Ongoing Phase 3 Trials Second Line

Some Ongoing Phase 3 Trials (cont)

Second Line

Some Ongoing Phase 3 TrialsFirst Line

Program Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)